USPTO Examiner BRISTOL LYNN ANNE - Art Unit 1643

Recent Applications

Detailed information about the 100 most recent patent applications.

Application NumberTitleFiling DateDisposal DateDispositionTime (months)Office ActionsRestrictionsInterviewAppeal
19242725COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEJune 2025February 2026Allow810YesNo
18942051COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASENovember 2024January 2026Allow1540YesNo
18755457ANTIBODIES BINDING TO FIBROBLAST ACTIVATION PROTEIN ALPHA AND DEATH RECEPTOR 4June 2024March 2025Allow910YesNo
18643312BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19April 2024October 2024Allow621NoNo
18623246BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD20 and CD19April 2024October 2024Allow720NoNo
18612854CD19/CD38 MULTISPECIFIC ANTIBODIESMarch 2024September 2024Allow520YesNo
18611460ANTIBODIES WITH MUTATED HEAVY CHAIN CONSTANT REGIONSMarch 2024October 2025Allow1840YesNo
18590651CYTOTOXICITY-INDUCING THERAPEUTIC AGENTFebruary 2024November 2025Allow2140YesNo
18408414PROTEINS THAT BIND SP17 INCLUDING FULLY-HUMAN ANTI-SP17 ANTIBODIESJanuary 2024February 2026Allow2540YesNo
18393322UNIVERSAL ANTI-CD22 CHIMERIC ANTIGEN RECEPTOR ENGINEERED IMMUNE CELLSDecember 2023July 2024Allow710NoNo
18491182CANINE MONOCLONAL ANTIBODIES AGAINST CANINE CYTOTOXIC T LYMPHOCYTE ASSOCIATED PROTEIN 4 (CTLA-4)October 2023June 2024Allow710NoNo
18464998COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDINGSeptember 2023September 2024Allow1220NoNo
18238210BISPECIFIC OR-GATE CHIMERIC ANTIGEN RECEPTOR RESPONSIVE TO CD19 and CD20August 2023February 2024Allow510YesNo
18451047MULTISPECIFIC ANTI-TCR DELTA VARIABLE 1 ANTIBODIESAugust 2023January 2025Allow1711YesNo
18361184SIGLEC-8 BINDING PROTEINS AND USES THEREOFJuly 2023May 2024Abandon910YesNo
18340367ANTIBODIES BINDING SIGLEC15 AND USES THEREOFJune 2023January 2026Allow3121NoNo
18186353Bi-Specific Monovalent Diabodies That are Capable of Binding CD19 and CD3, and Uses ThereofMarch 2023September 2025Abandon3010NoNo
18164514HEAVY CHAIN ANTIBODIES BINDING TO PSMAFebruary 2023September 2023Allow710NoNo
18164386COMPOSITIONS AND METHODS RELATED TO IL27 RECEPTOR BINDINGFebruary 2023August 2023Allow710YesNo
18155973Anti-Notch2 Antibodies and Conjugates and Methods of UseJanuary 2023March 2026Abandon3710NoNo
18150514COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEJanuary 2023July 2025Allow3020NoNo
18147331ANTIBODIES HAVING SPECIFICITY FOR BTN2 AND USES THEREOFDecember 2022September 2025Abandon3210NoNo
18145254ANTIBODIES TARGETING G-PROTEIN COUPLED RECEPTOR AND METHODS OF USEDecember 2022February 2026Allow3821YesNo
18067142RECOMBINANT MONOCLONAL ANTIBODIES AND CORRESPONDING ANTIGENS FOR COLON AND PANCREATIC CANCERSDecember 2022July 2025Allow3110NoNo
18063477BISPECIFIC ANTIBODIES AGAINST CEACAM5 AND CD47December 2022March 2026Abandon3920YesNo
18058699ANTI-PD-L1 ANTIBODIESNovember 2022July 2025Allow3220NoNo
18055720ANTIBODY CONSTRUCTSNovember 2022July 2025Abandon3210NoNo
17922230ANTIGEN BINDING CONSTRUCTS TARGETING HER2 AND USES THEREOFOctober 2022December 2024Allow2540YesNo
17937750CD3 BINDING ANTIBODIESOctober 2022July 2025Abandon3310YesNo
17936331BISPECIFIC CHECKPOINT INHIBITOR ANTIBODIESSeptember 2022June 2025Abandon3210NoNo
17935815ANTIBODIES BINDING SIGLEC15 AND USES THEREOFSeptember 2022May 2023Allow711YesNo
17933277Antibody Constructs for CDH19 and CD3September 2022June 2025Allow3310NoNo
17931822Antibody Derivatives with Conditionally Enabled Effector FunctionSeptember 2022July 2025Abandon3440NoNo
17930074BINDING PROTEINS, INCLUDING ANTIBODIES, ANTIBODY DERIVATIVES AND ANTIBODY FRAGMENTS, THAT SPECIFICALLY BIND CD154 AND USES THEREOFSeptember 2022July 2025Abandon3411NoNo
17905694PVRIG Binding Protein And Its Medical UsesSeptember 2022January 2026Allow4010YesNo
17822978COMPOSITIONS AND METHODS FOR TREATMENT OF THYROID EYE DISEASEAugust 2022November 2022Allow310YesNo
17893998BTNL3 PROTEINS, NUCLEIC ACIDS AND ANTIBODIES AND USES THEREOFAugust 2022March 2025Abandon3110NoNo
17821143CD3 BINDING ANTIBODIESAugust 2022March 2025Abandon3110NoNo
17819819ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODSAugust 2022March 2025Abandon3110NoNo
17885692METHODS FOR INCREASING THE DIVERSITY OF MONOCLONAL ANTIBODIES PRODUCED AGAINST AN ANTIGENAugust 2022April 2025Abandon3210NoNo
17798738ANTI-SIRPA ANTIBODIES AND METHODS OF USEAugust 2022December 2025Abandon4010NoNo
17817599ANTI-THYROGLOBULIN T CELL RECEPTORSAugust 2022January 2025Allow3010NoNo
17871829TRISPECIFIC ANTIBODIESJuly 2022March 2025Abandon3110NoNo
17813857Therapeutic Biologic For Treatment Of Hepatocellular CarcinomaJuly 2022April 2025Allow3320NoNo
17811828METHODSJuly 2022March 2025Abandon3201NoNo
17810447BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPYJuly 2022September 2024Allow2710NoNo
17809941ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULESJune 2022February 2025Abandon3101NoNo
17809943ANTI-BETACELLULIN ANTIBODIES, FRAGMENTS THEREOF, AND MULTI-SPECIFIC BINDING MOLECULESJune 2022November 2025Allow4010YesNo
17847597MODIFIED CHIMERIC ANTIGEN RECEPTORS AND METHODS OF USEJune 2022July 2025Allow3621NoNo
17837633TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USEJune 2022February 2025Allow3220NoNo
17783344ANTI-BCMA/ANTI-4-1BB BISPECIFIC ANTIBODIES AND USES THEREOFJune 2022January 2026Allow4421YesNo
17782417HUMANIZED CLDN18.2 ANTIBODIESJune 2022February 2026Allow4420NoNo
17832307METHODSJune 2022February 2024Abandon2010NoNo
17827242CD229 Car T Cells And Methods Of Use ThereofMay 2022January 2025Abandon3101NoNo
17777188METHODS OF TREATING LUPUS NEPHRITIS USING INTERLEUKIN-17 (IL-17) ANTAGONISTSMay 2022November 2025Abandon4210NoNo
17736031MULTI-SPECIFIC BINDING PROTEINS THAT BIND CD33, NKG2D, AND CD16, AND METHODS OF USEMay 2022September 2023Abandon1621YesNo
17768701HUMAN BROADLY NEUTRALIZING ANTIBODIES AGAINST THE MEMBRANE-PROXIMAL EXTERNAL REGION OF HIV ENV FOR VACCINE DESIGN AND INTERVENTIONApril 2022January 2026Allow4520YesNo
17709592METHOD FOR IMPROVING AFFINITY OF ANTIBODY FOR ANTIGEN AND USE THEREOFMarch 2022November 2025Abandon4310NoNo
17705016ANTI-CEACAM5 ANTIBODIES AND USES THEREOFMarch 2022September 2025Allow4231YesNo
17702660Antibodies That Bind CD3 EpsilonMarch 2022March 2024Allow2331YesNo
17701764PROTEINS COMPRISING CD3 ANTIGEN BINDING DOMAINS AND USES THEREOFMarch 2022May 2024Allow2520YesNo
17701570BISPECIFIC ANTIBODIES TARGETING CD47 AND PD-L1 AND METHODS OF USE THEREOFMarch 2022November 2025Allow4441YesNo
17642130METHODS OF TREATING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) USING IL-17RA ANTIBODYMarch 2022September 2025Abandon4301NoNo
17685216METHODS OF USE OF ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIESMarch 2022November 2025Abandon4540NoNo
17685201ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIESMarch 2022November 2024Allow3220NoNo
17685206ANTI-CD19/ANTI-CD38 COMMON LIGHT CHAIN BISPECIFIC ANTIBODIESMarch 2022August 2025Allow4140NoNo
17682367PHARMACEUTICAL FORMULATIONS AND DOSAGE REGIMENS FOR MULTI-SPECIFIC BINDING PROTEINS THAT BIND HER2, NKG2D, AND CD16 FOR CANCER TREATMENTFebruary 2022October 2025Abandon4301NoNo
17681737TNFRSF14 / HVEM PROTEINS AND METHODS OF USE THEREOFFebruary 2022February 2026Abandon4821NoNo
17652557MODIFIED ANTIGEN BINDING POLYPEPTIDE CONSTRUCTS AND USES THEREOFFebruary 2022January 2025Allow3520NoNo
17636440Bispecific Antibody Targeting CD3 and CD20 and Use ThereofFebruary 2022February 2026Allow4821NoNo
17648747ENGINEERED IMMUNOGLOBULIN HEAVY CHAIN-LIGHT CHAIN PAIRS AND USES THEREOFJanuary 2022February 2025Allow3720NoNo
17582913ANTIBODIES AGAINST MICA AND/OR MICB AND USES THEREOFJanuary 2022March 2025Abandon3811NoNo
17581624T CELL RETARGETING HETERO-DIMERIC IMMUNOGLOBULINSJanuary 2022November 2024Abandon3410NoNo
17576344Anti-Polyubiquitin Multispecific AntibodiesJanuary 2022September 2024Allow3210NoNo
17576800METHOD FOR ELICITING AN IMMUNE RESPONSE TO AN IMMUNOGENJanuary 2022March 2025Abandon3811NoNo
17573640NOVEL ANTI-CD4 ANTIBODIESJanuary 2022September 2025Allow4430NoNo
17573145COMPOSITIONS AND METHODS FOR CROSSLINKING FC RECEPTORSJanuary 2022January 2025Abandon3611NoNo
17571794FAB Molecules with a Rodent Hinge Region and a Non-Rodent CH1 RegionJanuary 2022May 2025Abandon4021YesNo
17569487ANTI-SARS-COV-2 ANTIBODIES AND USES THEREOFJanuary 2022October 2024Abandon3401NoNo
17540044COMPOSITIONS FOR INCREASING HALF-LIFE OF A THERAPEUTIC AGENT IN LIVESTOCK ANIMALS AND METHODS OF USEDecember 2021June 2024Allow3011YesNo
17531199BIOLOGICAL MATERIALS AND USES THEREOFNovember 2021September 2024Abandon3401NoNo
17520748ANTI CANCER COMBINATION THERAPYNovember 2021October 2024Abandon3510NoNo
17517632ALLOGENEIC TUMOR CELL VACCINENovember 2021February 2026Abandon5251YesNo
17513217ANTI-PD1 ANTIBODIES AND THEIR USE AS THERAPEUTICS AND DIAGNOSTICSOctober 2021March 2025Abandon4120NoNo
17512837Single Domain Antibodies to SARS-CoV-2 Nucleocapsid ProteinOctober 2021June 2023Allow2011NoNo
17509351ANTI-NEUROPILIN ANTIGEN-BINDING PROTEINS AND METHODS OF USE THEREOFOctober 2021February 2025Abandon4020NoNo
17510160Anti-Abeta AntibodiesOctober 2021April 2022Abandon610NoNo
17505763AGONISTIC TRKB BINDING MOLECULES FOR THE TREATMENT OF EYE DISEASESOctober 2021October 2024Abandon3531NoNo
17499597BIOENGINEERED T CELL MEDIATED IMMUNITY, MATERIALS AND OTHER METHODS FOR MODULATING CLUSTER OF DIFFERENTIATION IV &/OR VIIIOctober 2021November 2023Allow2521YesNo
17499127ANTIBODY THERAPEUTICS THAT BIND CD137October 2021August 2025Abandon4630NoNo
17496240HETERODIMER MOLECULE BASED ON CH3 DOMAIN, AND PREPARATION METHOD AND USE THEREOFOctober 2021December 2024Allow3820YesNo
17601417HEAVY CHAIN ANTIBODIES BINDING TO PSMAOctober 2021August 2024Allow3410NoNo
17492444CD3 BINDING ANTIBODIESOctober 2021June 2022Allow820YesNo
17477651ANTI-HLA-DQ2.5 ANTIBODY AND ITS USE FOR THE TREATMENT OF CELIAC DISEASESeptember 2021May 2023Allow2031YesNo
17461365CHIMERIC ANTIGEN RECEPTOR EFFECTOR CELL SWITCHES WITH HUMANIZED TARGETING MOIETIES AND/OR OPTIMIZED CHIMERIC ANTIGEN RECEPTOR INTERACTING DOMAINS AND USES THEREOFAugust 2021December 2024Allow4021NoNo
17405861ANTI-CD27 AND ANTI-PD-L1 ANTIBODIES AND BISPECIFIC CONSTRUCTSAugust 2021March 2022Allow710NoNo
17398311AFFINITY-ENHANCED MONMERIC STREPTAVIDIN CHIMERIC ANTIGEN RECEPTOR (CAR)August 2021September 2024Abandon3820YesNo
17387399COMBINATION OF DR5 AGONIST AND ANTI-PD-1 ANTAGONIST AND METHODS OF USEJuly 2021April 2024Abandon3301NoNo
17385805INHIBITORY CHIMERIC ANTIGEN RECEPTORSJuly 2021April 2024Abandon3310NoNo
17377924ANTIBODIES SPECIFIC FOR IMMUNOGLOBULIN-LIKE TRANSCRIPT 3 (ILT3) AND USES THEREOFJuly 2021May 2024Allow3410NoNo

Appeals Overview

This analysis examines appeal outcomes and the strategic value of filing appeals for examiner BRISTOL, LYNN ANNE.

Patent Trial and Appeal Board (PTAB) Decisions

Total PTAB Decisions
10
Examiner Affirmed
5
(50.0%)
Examiner Reversed
5
(50.0%)
Reversal Percentile
70.0%
Higher than average

What This Means

With a 50.0% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is above the USPTO average, indicating that appeals have better success here than typical.

Strategic Value of Filing an Appeal

Total Appeal Filings
163
Allowed After Appeal Filing
36
(22.1%)
Not Allowed After Appeal Filing
127
(77.9%)
Filing Benefit Percentile
29.1%
Lower than average

Understanding Appeal Filing Strategy

Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.

In this dataset, 22.1% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.

Strategic Recommendations

Appeals to PTAB show good success rates. If you have a strong case on the merits, consider fully prosecuting the appeal to a Board decision.

Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.

Examiner BRISTOL, LYNN ANNE - Prosecution Strategy Guide

Executive Summary

Examiner BRISTOL, LYNN ANNE works in Art Unit 1643 and has examined 1,264 patent applications in our dataset. With an allowance rate of 57.4%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 36 months.

Allowance Patterns

Examiner BRISTOL, LYNN ANNE's allowance rate of 57.4% places them in the 18% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.

Office Action Patterns

On average, applications examined by BRISTOL, LYNN ANNE receive 2.37 office actions before reaching final disposition. This places the examiner in the 68% percentile for office actions issued. This examiner issues a slightly above-average number of office actions.

Prosecution Timeline

The median time to disposition (half-life) for applications examined by BRISTOL, LYNN ANNE is 36 months. This places the examiner in the 34% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.

Interview Effectiveness

Conducting an examiner interview provides a +49.7% benefit to allowance rate for applications examined by BRISTOL, LYNN ANNE. This interview benefit is in the 93% percentile among all examiners. Recommendation: Interviews are highly effective with this examiner and should be strongly considered as a prosecution strategy. Per MPEP § 713.10, interviews are available at any time before the Notice of Allowance is mailed or jurisdiction transfers to the PTAB.

Request for Continued Examination (RCE) Effectiveness

When applicants file an RCE with this examiner, 19.4% of applications are subsequently allowed. This success rate is in the 20% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.

After-Final Amendment Practice

This examiner enters after-final amendments leading to allowance in 50.4% of cases where such amendments are filed. This entry rate is in the 76% percentile among all examiners. Strategic Recommendation: This examiner is highly receptive to after-final amendments compared to other examiners. Per MPEP § 714.12, after-final amendments may be entered "under justifiable circumstances." Consider filing after-final amendments with a clear showing of allowability rather than immediately filing an RCE, as this examiner frequently enters such amendments.

Pre-Appeal Conference Effectiveness

When applicants request a pre-appeal conference (PAC) with this examiner, 82.4% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.

Appeal Withdrawal and Reconsideration

This examiner withdraws rejections or reopens prosecution in 88.5% of appeals filed. This is in the 82% percentile among all examiners. Of these withdrawals, 83.1% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner frequently reconsiders rejections during the appeal process compared to other examiners. Per MPEP § 1207.01, all appeals must go through a mandatory appeal conference. Filing a Notice of Appeal may prompt favorable reconsideration even before you file an Appeal Brief.

Petition Practice

When applicants file petitions regarding this examiner's actions, 64.1% are granted (fully or in part). This grant rate is in the 69% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.

Examiner Cooperation and Flexibility

Examiner's Amendments: This examiner makes examiner's amendments in 8.5% of allowed cases (in the 91% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.

Quayle Actions: This examiner issues Ex Parte Quayle actions in 9.1% of allowed cases (in the 88% percentile). Per MPEP § 714.14, a Quayle action indicates that all claims are allowable but formal matters remain. This examiner frequently uses Quayle actions compared to other examiners, which is a positive indicator that once substantive issues are resolved, allowance follows quickly.

Prosecution Strategy Recommendations

Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:

  • Prepare for rigorous examination: With a below-average allowance rate, ensure your application has strong written description and enablement support. Consider filing a continuation if you need to add new matter.
  • Prioritize examiner interviews: Interviews are highly effective with this examiner. Request an interview after the first office action to clarify issues and potentially expedite allowance.
  • Consider after-final amendments: This examiner frequently enters after-final amendments. If you can clearly overcome rejections with claim amendments, file an after-final amendment before resorting to an RCE.
  • Appeal filing as negotiation tool: This examiner frequently reconsiders rejections during the appeal process. Filing a Notice of Appeal may prompt favorable reconsideration during the mandatory appeal conference.
  • Examiner cooperation: This examiner frequently makes examiner's amendments to place applications in condition for allowance. If you are close to allowance, the examiner may help finalize the claims.

Relevant MPEP Sections for Prosecution Strategy

  • MPEP § 713.10: Examiner interviews - available before Notice of Allowance or transfer to PTAB
  • MPEP § 714.12: After-final amendments - may be entered "under justifiable circumstances"
  • MPEP § 1002.02(c): Petitionable matters to Technology Center Director
  • MPEP § 1004: Actions requiring primary examiner signature (allowances, final rejections, examiner's answers)
  • MPEP § 1207.01: Appeal conferences - mandatory for all appeals
  • MPEP § 1214.07: Reopening prosecution after appeal

Important Disclaimer

Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.

No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.

Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.

Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.